Citius Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Citius Pharmaceuticals, Inc. (CTXR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$8.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$8.86M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$21.23M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$8.22M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$7.96M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$37.43M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$40.19M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$33.69M.
- Citius Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$33.64M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.86M 10-Q · filed 2026-08-14 | -$30.09M derived: sum of 2 quarters · filed 2026-08-14 | -$38.31M 10-Q · filed 2026-08-14 | -$46.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$21.23M 10-Q · filed 2026-05-15 | -$29.45M 10-Q · filed 2026-05-15 | -$37.41M derived: sum of 3 quarters · filed 2026-05-15 | -$46.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$8.22M 10-Q · filed 2026-02-13 | -$16.18M derived: sum of 2 quarters · filed 2026-02-13 | -$24.97M derived: sum of 3 quarters · filed 2026-08-14 | -$35.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$16.75M derived: sum of 2 quarters · filed 2026-08-14 | -$27.67M derived: sum of 3 quarters · filed 2026-08-14 | -$37.43M 10-K · filed 2025-12-23 |
| 2025-06-30 | -$8.79M 10-Q · filed 2026-08-14 | -$19.71M derived: sum of 2 quarters · filed 2026-08-14 | -$29.47M 10-Q · filed 2026-08-14 | -$40.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$10.92M 10-Q · filed 2026-05-15 | -$20.68M 10-Q · filed 2026-05-15 | -$32.20M derived: sum of 3 quarters · filed 2026-05-15 | -$43.10M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$9.77M 10-Q · filed 2026-02-13 | -$21.28M derived: sum of 2 quarters · filed 2026-02-13 | -$32.18M derived: sum of 3 quarters · filed 2026-02-13 | -$40.72M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | -$11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$22.41M derived: sum of 2 quarters · filed 2025-12-23 | -$30.95M derived: sum of 3 quarters · filed 2025-12-23 | -$40.19M 10-K · filed 2025-12-23 |
| 2024-06-30 | -$10.89M 10-Q · filed 2025-08-12 | -$19.44M derived: sum of 2 quarters · filed 2025-08-12 | -$28.67M 10-Q · filed 2025-08-12 | -$39.77M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$8.54M 10-Q · filed 2025-05-14 | -$17.78M 10-Q · filed 2025-05-14 | -$28.87M derived: sum of 3 quarters · filed 2025-05-14 | -$37.35M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$9.23M 10-Q · filed 2025-02-14 | -$20.33M derived: sum of 2 quarters · filed 2025-02-14 | -$28.81M derived: sum of 3 quarters · filed 2025-02-14 | |
| 2023-09-30 | -$11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | -$19.57M derived: sum of 2 quarters · filed 2024-12-27 | -$33.69M 10-K · filed 2024-12-27 | |
| 2023-06-30 | -$8.48M 10-Q · filed 2024-08-12 | -$22.60M 10-Q · filed 2024-08-12 | ||
| 2022-09-30 | -$7.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | -$16.85M derived: sum of 2 quarters · filed 2023-12-29 | -$33.64M 10-K · filed 2023-12-29 | |
| 2022-06-30 | -$8.86M 10-Q · filed 2022-08-11 | -$25.65M 10-Q · filed 2022-08-11 | ||
| 2021-09-30 | -$4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | -$12.24M derived: sum of 2 quarters · filed 2022-12-22 | -$24.51M 10-K · filed 2022-12-22 | |
| 2021-06-30 | -$7.27M 10-Q · filed 2022-08-11 | -$19.54M 10-Q · filed 2022-08-11 | ||
| 2020-09-30 | -$4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | -$8.80M derived: sum of 2 quarters · filed 2021-12-15 | -$17.55M 10-K · filed 2021-12-15 | |
| 2020-06-30 | -$4.68M 10-Q · filed 2021-08-12 | -$13.43M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |